Allogene Therapeutics, Inc. Comprehensive Income
Allogene Therapeutics, Inc. (ALLO) reported Comprehensive Income of -$43.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$43.01M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$43.06M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$38.78M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$41.12M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$190.53M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$256.72M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$318.29M.
- Allogene Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$347.77M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$43.01M 10-Q · filed 2026-08-12 | -$86.07M 10-Q · filed 2026-08-12 | -$124.85M derived: sum of 3 quarters · filed 2026-08-12 | -$165.97M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | -$43.06M 10-Q · filed 2026-05-13 | -$81.83M derived: sum of 2 quarters · filed 2026-05-13 | -$122.95M derived: sum of 3 quarters · filed 2026-05-13 | -$173.99M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | -$38.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$79.90M derived: sum of 2 quarters · filed 2026-03-12 | -$130.93M derived: sum of 3 quarters · filed 2026-08-12 | -$190.53M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | -$41.12M 10-Q · filed 2025-11-06 | -$92.15M derived: sum of 2 quarters · filed 2026-08-12 | -$151.75M 10-Q · filed 2025-11-06 | -$211.94M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | -$51.03M 10-Q · filed 2026-08-12 | -$110.63M 10-Q · filed 2026-08-12 | -$170.82M derived: sum of 3 quarters · filed 2026-08-12 | -$236.17M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | -$59.60M 10-Q · filed 2026-05-13 | -$119.79M derived: sum of 2 quarters · filed 2026-05-13 | -$185.14M derived: sum of 3 quarters · filed 2026-05-13 | -$251.35M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | -$60.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$125.54M derived: sum of 2 quarters · filed 2026-03-12 | -$191.75M derived: sum of 3 quarters · filed 2026-03-12 | -$256.72M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | -$65.36M 10-Q · filed 2025-11-06 | -$131.57M derived: sum of 2 quarters · filed 2025-11-06 | -$196.54M 10-Q · filed 2025-11-06 | -$280.86M derived: sum of 4 quarters · filed 2025-11-06 | |||||
| 2024-06-30 | -$66.21M 10-Q · filed 2025-08-13 | -$131.18M 10-Q · filed 2025-08-13 | -$215.50M derived: sum of 3 quarters · filed 2025-08-13 | -$276.35M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$64.97M 10-Q · filed 2025-05-13 | -$149.29M derived: sum of 2 quarters · filed 2025-05-13 | -$210.14M derived: sum of 3 quarters · filed 2025-05-13 | -$287.29M derived: sum of 4 quarters · filed 2025-05-13 | |||||
| 2023-12-31 | -$84.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$145.17M derived: sum of 2 quarters · filed 2025-03-13 | -$222.32M derived: sum of 3 quarters · filed 2025-03-13 | -$318.29M 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | -$60.85M 10-Q · filed 2024-11-07 | -$59.88M 10-Q · filed 2023-11-02 | -$138.00M derived: sum of 2 quarters · filed 2024-11-07 | -$233.97M 10-Q · filed 2024-11-07 | -$230.49M 10-Q · filed 2023-11-02 | -$328.21M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$77.15M 10-Q · filed 2024-08-07 | -$75.91M 10-Q · filed 2023-08-02 | -$173.13M 10-Q · filed 2024-08-07 | -$170.62M 10-Q · filed 2023-08-02 | -$267.37M derived: sum of 3 quarters · filed 2024-08-07 | -$353.10M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | -$95.98M 10-Q · filed 2024-05-13 | -$94.71M 10-Q · filed 2023-05-03 | -$190.22M derived: sum of 2 quarters · filed 2024-05-13 | -$275.95M derived: sum of 3 quarters · filed 2024-05-13 | -$358.46M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$94.24M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | -$179.97M derived: sum of 2 quarters · filed 2024-03-14 | -$262.48M derived: sum of 3 quarters · filed 2024-03-14 | -$347.77M 10-K/A · filed 2024-03-14 | -$339.99M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | -$85.73M 10-K · filed 2024-03-14 | -$84.63M 10-Q · filed 2022-11-02 | -$168.24M derived: sum of 2 quarters · filed 2024-03-14 | -$253.53M 10-K · filed 2024-03-14 | -$248.18M 10-Q · filed 2022-11-02 | -$255.61M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | -$82.51M 10-K · filed 2024-03-14 | -$77.01M 10-Q · filed 2022-08-09 | -$167.80M 10-K · filed 2024-03-14 | -$163.54M 10-Q · filed 2022-08-09 | -$169.88M derived: sum of 3 quarters · filed 2024-03-14 | -$248.13M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$85.29M 10-K · filed 2024-03-14 | -$86.53M 10-Q · filed 2022-05-04 | -$87.37M derived: sum of 2 quarters · filed 2024-03-14 | -$165.62M derived: sum of 3 quarters · filed 2024-03-14 | -$236.79M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | -$2.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$80.33M derived: sum of 2 quarters · filed 2024-03-14 | -$151.50M derived: sum of 3 quarters · filed 2024-03-14 | -$184.89M 10-K/A · filed 2024-03-14 | -$259.84M 10-K · filed 2022-02-23 | ||||
| 2021-09-30 | -$78.25M 10-Q · filed 2022-11-02 | -$149.42M derived: sum of 2 quarters · filed 2022-11-02 | -$182.80M 10-Q · filed 2022-11-02 | -$318.22M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-06-30 | -$71.17M 10-Q · filed 2022-08-09 | -$104.55M 10-Q · filed 2022-08-09 | -$239.97M derived: sum of 3 quarters · filed 2024-03-14 | -$307.04M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-03-31 | -$33.38M 10-Q · filed 2022-05-04 | -$168.80M derived: sum of 2 quarters · filed 2024-03-14 | -$235.87M derived: sum of 3 quarters · filed 2024-03-14 | -$296.63M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2020-12-31 | -$135.41M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$202.49M derived: sum of 2 quarters · filed 2024-03-14 | -$263.24M derived: sum of 3 quarters · filed 2024-03-14 | -$317.26M 10-K/A · filed 2024-03-14 | -$251.10M 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | -$67.07M 10-Q · filed 2021-11-04 | -$127.83M derived: sum of 2 quarters · filed 2021-11-04 | -$181.84M 10-Q · filed 2021-11-04 | -$243.59M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2020-06-30 | -$60.75M 10-Q · filed 2021-08-04 | -$114.77M 10-Q · filed 2021-08-04 | -$176.52M derived: sum of 3 quarters · filed 2022-02-23 | -$227.55M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2020-03-31 | -$54.02M 10-Q · filed 2021-05-05 | -$115.77M derived: sum of 2 quarters · filed 2022-02-23 | -$166.80M derived: sum of 3 quarters · filed 2022-02-23 | -$207.28M derived: sum of 4 quarters · filed 2022-02-23 | |||||
| 2019-12-31 | -$61.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$112.78M derived: sum of 2 quarters · filed 2022-02-23 | -$153.27M derived: sum of 3 quarters · filed 2022-02-23 | -$183.75M 10-K · filed 2022-02-23 | |||||
| 2019-09-30 | -$51.03M 10-Q · filed 2020-11-04 | -$91.52M derived: sum of 2 quarters · filed 2020-11-04 | -$122.00M 10-Q · filed 2020-11-04 | -$152.06M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-06-30 | -$40.49M 10-Q · filed 2020-08-05 | -$70.97M 10-Q · filed 2020-08-05 | -$101.03M derived: sum of 3 quarters · filed 2021-02-25 | -$144.67M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | -$30.49M 10-Q · filed 2020-05-06 | -$60.54M derived: sum of 2 quarters · filed 2021-02-25 | -$104.19M derived: sum of 3 quarters · filed 2021-02-25 | -$239.09M derived: sum of 4 quarters · filed 2021-02-25 | |||||
| 2018-12-31 | -$30.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$73.70M derived: sum of 2 quarters · filed 2021-02-25 | -$208.60M derived: sum of 3 quarters · filed 2021-02-25 | -$211.20M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | -$43.65M 10-Q · filed 2019-11-05 | -$178.55M derived: sum of 2 quarters · filed 2019-11-05 | -$181.14M 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | -$134.90M 10-Q · filed 2019-08-07 | -$137.50M 10-Q · filed 2019-08-07 | |||||||
| 2018-03-31 | -$2.60M 10-Q · filed 2019-05-07 | ||||||||
| 2017-12-31 | -$2.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |